JP2020500215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500215A5 JP2020500215A5 JP2019545725A JP2019545725A JP2020500215A5 JP 2020500215 A5 JP2020500215 A5 JP 2020500215A5 JP 2019545725 A JP2019545725 A JP 2019545725A JP 2019545725 A JP2019545725 A JP 2019545725A JP 2020500215 A5 JP2020500215 A5 JP 2020500215A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- aliphatic
- rings
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 102
- 125000001931 aliphatic group Chemical group 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 57
- 125000004043 oxo group Chemical group O=* 0.000 claims description 50
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 150000002367 halogens Chemical class 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 27
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000002723 alicyclic group Chemical group 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 208000015114 central nervous system disease Diseases 0.000 claims description 17
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 201000004810 Vascular dementia Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 208000020016 psychiatric disease Diseases 0.000 claims description 8
- 208000014094 Dystonic disease Diseases 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- 208000029560 autism spectrum disease Diseases 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- 208000010118 dystonia Diseases 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 208000027534 Emotional disease Diseases 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 4
- 206010034010 Parkinsonism Diseases 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229960004502 levodopa Drugs 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000003340 mental effect Effects 0.000 claims description 3
- 230000036651 mood Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 208000036640 Asperger disease Diseases 0.000 claims description 2
- 201000006062 Asperger syndrome Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000010482 CADASIL Diseases 0.000 claims description 2
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 2
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims description 2
- 208000024254 Delusional disease Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 208000018526 Narcotic-Related disease Diseases 0.000 claims description 2
- 208000028361 Penetrating Head injury Diseases 0.000 claims description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 2
- 206010036631 Presenile dementia Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010049644 Williams syndrome Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 150000007824 aliphatic compounds Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000005040 opiate dependence Diseases 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 230000000946 synaptic effect Effects 0.000 claims description 2
- 230000003956 synaptic plasticity Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 208000037820 vascular cognitive impairment Diseases 0.000 claims 1
- 0 C*C(c(c(**)c(C)c(C(C)C)c1*C)c1N)=* Chemical compound C*C(c(c(**)c(C)c(C(C)C)c1*C)c1N)=* 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- WZUKCWZQRDFYBY-UHFFFAOYSA-O CC(c(c([NH2+]C)c1C)nc([ClH]C)c1[ClH](C)=C)=N Chemical compound CC(c(c([NH2+]C)c1C)nc([ClH]C)c1[ClH](C)=C)=N WZUKCWZQRDFYBY-UHFFFAOYSA-O 0.000 description 1
- QAXGZFQDGNOCEI-UHFFFAOYSA-N Cc1ncc(C[n](c2ncccc22)nc2-c2nnc(C(F)(F)F)[nH]2)cn1 Chemical compound Cc1ncc(C[n](c2ncccc22)nc2-c2nnc(C(F)(F)F)[nH]2)cn1 QAXGZFQDGNOCEI-UHFFFAOYSA-N 0.000 description 1
- 206010050389 Cerebral ataxia Diseases 0.000 description 1
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 description 1
- MERGIIICASZYJB-UHFFFAOYSA-N FC(c1nnc(-c2n[n](Cc3ccccc3F)c3ncccc23)[nH]1)(F)F Chemical compound FC(c1nnc(-c2n[n](Cc3ccccc3F)c3ncccc23)[nH]1)(F)F MERGIIICASZYJB-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- -1 fluoro compound Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419086P | 2016-11-08 | 2016-11-08 | |
| US62/419,086 | 2016-11-08 | ||
| PCT/US2017/060305 WO2018089330A2 (en) | 2016-11-08 | 2017-11-07 | Sgc stimulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500215A JP2020500215A (ja) | 2020-01-09 |
| JP2020500215A5 true JP2020500215A5 (https=) | 2020-12-17 |
| JP7199364B2 JP7199364B2 (ja) | 2023-01-05 |
Family
ID=60473639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545725A Active JP7199364B2 (ja) | 2016-11-08 | 2017-11-07 | ｓＧＣ刺激剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11180493B2 (https=) |
| EP (1) | EP3538520B1 (https=) |
| JP (1) | JP7199364B2 (https=) |
| CN (1) | CN110267949A (https=) |
| AU (1) | AU2017356887B2 (https=) |
| CA (1) | CA3042713A1 (https=) |
| ES (1) | ES3059583T3 (https=) |
| IL (1) | IL266372B2 (https=) |
| MA (1) | MA46755A (https=) |
| PH (1) | PH12019501017A1 (https=) |
| SG (1) | SG10202104876SA (https=) |
| WO (1) | WO2018089330A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110267949A (zh) | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | sGC刺激剂 |
| ES2924359T3 (es) | 2017-04-11 | 2022-10-06 | Sunshine Lake Pharma Co Ltd | Compuestos de indazol sustituidos con flúor y usos de los mismos |
| AR113811A1 (es) | 2017-10-31 | 2020-06-10 | Hoffmann La Roche | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
| KR20250141845A (ko) * | 2018-07-11 | 2025-09-29 | 티센토 쎄라퓨틱스 인크. | 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도 |
| CN113302193A (zh) | 2019-01-11 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| CN110305125B (zh) * | 2019-06-06 | 2021-09-03 | 山东新华制药股份有限公司 | 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 |
| CN110669045A (zh) * | 2019-09-05 | 2020-01-10 | 南通大学 | 一种1-甲基-[1,5-a]-吡啶并咪唑-3-腈及其化学合成方法 |
| EP4472620A1 (en) | 2022-02-01 | 2024-12-11 | Charité - Universitätsmedizin Berlin | A soluble guanylat cyclase activator for treating chronic vascular dysfunction |
| CN118772140B (zh) * | 2023-04-07 | 2026-04-17 | 四川大学 | 一类化合物及其在治疗hDHODH介导的疾病中的用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (de) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| PT1140012E (pt) | 1998-12-17 | 2004-05-31 | Alza Corp | Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
| BRPI0413363A (pt) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase |
| DE102006020327A1 (de) | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| WO2009094242A1 (en) | 2008-01-24 | 2009-07-30 | Merck & Co., Inc. | Angiotensin ii receptor antagonists |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| KR20110133034A (ko) | 2009-02-26 | 2011-12-09 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 시클라제 활성화제 |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| KR20140019004A (ko) | 2010-05-27 | 2014-02-13 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 시클라제 활성화제 |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CN104039784B (zh) | 2011-09-02 | 2017-08-22 | 拜耳知识产权有限责任公司 | 取代的增环嘧啶及其用途 |
| WO2014042263A1 (ja) | 2012-09-14 | 2014-03-20 | 田辺三菱製薬株式会社 | 新規レニン阻害薬 |
| EA033168B1 (ru) | 2013-03-15 | 2019-09-30 | Сайклерион Терапьютикс, Инк. | СТИМУЛЯТОРЫ sGC |
| CA2928998A1 (en) * | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| US20180344735A1 (en) * | 2015-12-14 | 2018-12-06 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
| WO2017108441A1 (en) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Treatment of cognitive impairment with cgc stimulator |
| WO2017121700A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
| ES2972711T3 (es) * | 2016-11-08 | 2024-06-14 | Tisento Therapeutics Inc | Tratamiento de enfermedades del CNS con estimuladores de la GCs |
| CN110267949A (zh) * | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | sGC刺激剂 |
-
2017
- 2017-11-07 CN CN201780081092.2A patent/CN110267949A/zh active Pending
- 2017-11-07 MA MA046755A patent/MA46755A/fr unknown
- 2017-11-07 JP JP2019545725A patent/JP7199364B2/ja active Active
- 2017-11-07 CA CA3042713A patent/CA3042713A1/en active Pending
- 2017-11-07 AU AU2017356887A patent/AU2017356887B2/en not_active Ceased
- 2017-11-07 US US16/348,377 patent/US11180493B2/en active Active
- 2017-11-07 IL IL266372A patent/IL266372B2/en unknown
- 2017-11-07 EP EP17804735.3A patent/EP3538520B1/en active Active
- 2017-11-07 SG SG10202104876SA patent/SG10202104876SA/en unknown
- 2017-11-07 ES ES17804735T patent/ES3059583T3/es active Active
- 2017-11-07 WO PCT/US2017/060305 patent/WO2018089330A2/en not_active Ceased
-
2019
- 2019-05-08 PH PH12019501017A patent/PH12019501017A1/en unknown
-
2021
- 2021-09-27 US US17/485,858 patent/US12435080B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500215A5 (https=) | ||
| JP2011515482A5 (https=) | ||
| EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2018505898A5 (https=) | ||
| CA2441565A1 (en) | Bisarylamines as potassium channel openers | |
| JP2014507455A5 (https=) | ||
| JP2021522206A5 (https=) | ||
| JP2010529081A5 (https=) | ||
| JP2021528427A5 (https=) | ||
| JP2017506666A (ja) | 高インスリン血症に関連した症状の処置 | |
| CA2540768A1 (en) | Pyrazolo and imidazo-pyrimidine derivatives | |
| EP2970125A1 (en) | Substituted naphthyridine and quinoline compounds as mao inhibitors | |
| JP2006519868A5 (https=) | ||
| JP2010505794A5 (https=) | ||
| RU2015101532A (ru) | Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5 | |
| JP2015516429A5 (https=) | ||
| RU2009143104A (ru) | Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии | |
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| JP2013544277A5 (https=) | ||
| RU2015101512A (ru) | Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5 | |
| JP2023507569A5 (https=) | ||
| JP6673218B2 (ja) | ジヒドロナフタレン誘導体 | |
| JP2019534327A5 (https=) | ||
| KR20230021121A (ko) | Gpr65의 조절제로서 n-페닐아미노카보닐 피리디노-, 피리미디노 및 벤조-트로판 |